Cerenovus launches largest global registry to study stroke-inducing bloo...
Company Also Receives European CE Mark Approval for Novel Stroke Technology Designed for Difficult to Extract Blood ClotsIRVINE, Calif., Dec. 10, 2018 -- Johnson & Johnson Medical Devices Companies* today announced that its CERENOVUS business has launched the single largest global registry, the EXCELLENT Registry, to collect and analyze stroke-inducing blood clots removed from the brain with its EMBOTRAP II Revascularization Device, a next generation stent retriever used in mechanical thrombectomy.